RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer (J Clin Invest, May 2013)

The PI3K signaling pathway regulates diverse cellular processes including proliferation, survival and metabolism and is aberrantly activated in human cancer. As such, numerous compounds targeting the PI3K pathway are currently being clinically evaluated for the treatment of cancer and several have shown some early indications of efficacy in breast cancer. However, resistance against these agents,

Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer (EMBO Mol Med, May 2013)

Epithelial ovarian cancer (EOC) is hallmarked by a high degree of heterogeneity. To address this heterogeneity, a classification scheme was developed based on gene expression patterns of 1538 tumours. Five, biologically distinct subgroups — Epi-A, Epi-B, Mes, Stem-A and Stem-B — exhibited significantly distinct clinicopathological characteristics, deregulated pathways and patient prognoses, and were validated using

NUS Chancellor, His Excellency Dr Tony Tan visits CSI

CSI Singapore had the great pleasure of welcoming our NUS Chancellor, His Excellency Dr Tony Tan Keng Yam, to the Institute on 15th May 2013, where he enjoyed a tour of our research facilities and laboratories. Hosted by our Deputy Director, A/Prof Chng Wee Joo, His Excellency was presented with a background of CSI’s history,

LIN28/LIN28B: An Emerging Oncogenic Driver in Cancer Stem Cells (Int J Biochem Cell Biol, May 2013)

LIN28 (LIN28A) is a reprogramming factor and conserved RNA-binding protein. LIN28B is the only homolog of LIN28 in humans, sharing structure and certain function. LIN28/LIN28B has been identified to be overexpressed in a wide range of solid tumors and hematological malignancies. Blockage of let-7 miRNA biogensis and subsequent derepression of let-7 miRNA target genes by